Axon Enterprise (NASDAQ:AXON) Insider Sells $800,000.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) insider Isaiah Fields sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the sale, the insider directly owned 52,813 shares of the company’s stock, valued at approximately $21,125,200. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Isaiah Fields also recently made the following trade(s):

• On Friday, February 27th, Isaiah Fields sold 2,000 shares of Axon Enterprise stock. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00.

Axon Enterprise Stock Down 0.2%

Shares of AXON traded down $0.70 during midday trading on Tuesday, hitting $385.30. The stock had a trading volume of 1,295,994 shares, compared to its average volume of 1,074,651. The company has a 50 day simple moving average of $414.25 and a two-hundred day simple moving average of $499.29. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91. The firm has a market cap of $31.06 billion, a price-to-earnings ratio of 154.74, a price-to-earnings-growth ratio of 7.02 and a beta of 1.44. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same quarter last year, the business posted $1.47 EPS. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, analysts anticipate that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Institutional Trading of Axon Enterprise

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA lifted its position in shares of Axon Enterprise by 30.1% in the first quarter. Glenmede Trust Co. NA now owns 2,445 shares of the biotechnology company’s stock valued at $1,038,000 after buying an additional 565 shares during the last quarter. Wellington Grp LLC lifted its position in shares of Axon Enterprise by 47.1% in the first quarter. Wellington Grp LLC now owns 575 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 184 shares during the last quarter. Arkadios Wealth Advisors lifted its position in shares of Axon Enterprise by 3.5% in the first quarter. Arkadios Wealth Advisors now owns 3,792 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 127 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Axon Enterprise by 10.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,736 shares of the biotechnology company’s stock valued at $737,000 after buying an additional 162 shares during the last quarter. Finally, Empowered Funds LLC lifted its position in shares of Axon Enterprise by 90.1% in the first quarter. Empowered Funds LLC now owns 6,320 shares of the biotechnology company’s stock valued at $2,684,000 after buying an additional 2,996 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on AXON shares. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. UBS Group cut their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.